Impact Factor 5.511

Among the world's top 10 most-cited Immunology journals

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2018.03018


 Franziska Eckert1*,  Karin Schilbach1, Lukas Klumpp1, 2, Lilia Bardoscia1, 3, Efe C. Sezgin1,  Matthias Schwab2, 4,  Daniel Zips1 and  Stephan M. Huber1
  • 1Universitätsklinikum Tübingen, Universität Tübingen, Germany
  • 2Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie (IKP), Germany
  • 3Università degli Studi di Brescia, Italy
  • 4Pharmakologie, Toxikologie und Klinische Pharmazie, Fachbereich Pharmazie und Biochemie, Universität Tübingen, Germany

Cancer immunotherapy has been established as standard of care in different tumor entities. After the first reports on synergistic effects with radiotherapy and the induction of abscopal effects – tumor shrinkage outside the irradiated volume attributed to immunological effects of radiotherapy – several treatment combinations have been evaluated. Different immunotherapy strategies (e.g. immune checkpoint inhibition, vaccination, cytokine based therapies) have been combined with local tumor irradiation in preclinical models. Clinical trials are ongoing in different cancer entities with a broad range of immunotherapeutics and radiation schedules. SDF-1 (CXCL12)/CXCR4 signaling has been described to play a major role in tumor biology, especially in hypoxia adaptation, metastasis and migration. Local tumor irradiation is a known inducer of SDF-1 expression and release. CXCR4 also plays a major role in immunological processes. CXCR4 antagonists have been approved for the use of hematopoietic stem cell mobilization from the bone marrow. In addition, several groups reported an influence of the SDF-1/CXCR4 axis on intratumoral immune cell subsets and anti-tumor immune response. The aim of this review is to merge the knowledge on the role of SDF-1/CXCR4 in tumor biology, radiotherapy and immunotherapy of cancer and in combinatorial approaches.

Keywords: Cancer, Immunotherapy, Radiotherapy, CXCR4, CXCL12, SDF1, T cells, Dendritic Cells, NK cells, Regulatory T (Treg) cells

Received: 29 Aug 2018; Accepted: 06 Dec 2018.

Edited by:

Christian Ostheimer, Martin Luther University of Halle-Wittenberg, Germany

Reviewed by:

Viktor Umansky, German Cancer Research Center (DKFZ), Germany
Luis De La Cruz-Merino, Hospital Universitario Virgen Macarena, Spain
Magdalena Plebanski, RMIT University, Australia  

Copyright: © 2018 Eckert, Schilbach, Klumpp, Bardoscia, Sezgin, Schwab, Zips and Huber. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Franziska Eckert, Universitätsklinikum Tübingen, Universität Tübingen, Tübingen, Germany,